Labeling a clear PET scan as a "remission" ignores the biological reality: it’s essentially a high-interest loan taken out against the patient’s soma. We celebrate the results, but we’re often blind to the fact that the treatment has aged the patient’s hematopoietic system and vascular endothelium by fifteen years in just six months. It forces us to ask whether oncology’s greatest victories are actually gerontology’s most tragic losses.

We’re currently trapped in a sequential fallacy. We treat the tumor as an isolated predator, using weapons—cisplatin, radiation, even some immunotherapies—that effectively scorch the very epigenetic landscape we’re trying to preserve. We cure the disease by accelerating the decline. It’s like congratulating a survivor for crossing the finish line when we’ve broken their legs to get them there.

If we accept that we can rewind the epigenetic clock, then our definition of a "cure" becomes a moral crisis. Leaving a 40-year-old breast cancer survivor with the senescent burden and inflammatory profile of a 60-year-old isn’t just a side effect—it’s an unfilled prescription. We’re leaving them in a biological debt we have the theoretical tools to cancel, yet we stop the moment we hit "clearance." Why are we funding the fire extinguisher but not the reconstruction?

We need a paradigm shift where Systemic Rejuvenative Therapy is the mandatory second half of every oncological protocol. We shouldn’t just be aiming for "cancer-free"; we should be aiming for "chronological-biological parity." To save a life only to hand it over to the accelerated entropy of induced senescence is a half-measure we can't justify anymore.

The critics aren't wrong—the regulatory hurdles for "rejuvenation-as-aftercare" are massive, and the toxicology of post-treatment reprogramming is a minefield. But we can’t keep patting ourselves on the back for saving lives while we quietly strip away the vitality that makes those lives worth living.

If you’re working on targeted senolytics or transient reprogramming specifically for post-chemo cohorts, let’s talk. We need to stop treating survival as a destination and start treating it as an investment that requires maintenance.